Liminatus Pharma Inc Cl A (LIMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,207 | -2,038 | -214 | 0 | -3,546 |
| Depreciation Amortization | 2 | 1 | 1 | N/A | 0 |
| Other Working Capital | -3,495 | -3,853 | -2,182 | 0 | 555 |
| Other Operating Activity | 3,736 | -3,687 | -6,580 | 0 | 1,540 |
| Operating Cash Flow | $-9,963 | $-9,577 | $-8,976 | $N/A | $-1,451 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | -13 | N/A | N/A | 0 |
| Net Acquisitions | -775 | -775 | -775 | N/A | -2,850 |
| Investing Cash Flow | $-788 | $-788 | $-775 | $N/A | $-2,850 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 4,340 | 4,340 | 4,340 | N/A | 3,923 |
| Common Stock Issued | 10,557 | 10,557 | 10,557 | N/A | N/A |
| Other Financing Activity | -3,864 | -3,864 | -3,864 | 0 | 0 |
| Financing Cash Flow | $11,033 | $11,033 | $11,033 | $N/A | $3,923 |
| Beginning Cash Position | 56 | 56 | 56 | N/A | 434 |
| End Cash Position | 338 | 725 | 1,338 | N/A | 56 |
| Net Cash Flow | $281 | $668 | $1,282 | $N/A | $-378 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,963 | -9,577 | -8,976 | N/A | -1,451 |
| Capital Expenditure | -13 | -13 | N/A | N/A | N/A |
| Free Cash Flow | -9,976 | -9,590 | -8,976 | 0 | -1,451 |